582 related articles for article (PubMed ID: 34097135)
1. Current Status of CAR T Cell Therapy for Leukemias.
Harris K; LaBelle JL; Bishop MR
Curr Treat Options Oncol; 2021 Jun; 22(7):62. PubMed ID: 34097135
[TBL] [Abstract][Full Text] [Related]
2. Advances in the development of chimeric antigen receptor-T-cell therapy in B-cell acute lymphoblastic leukemia.
Zhang X; Li JJ; Lu PH
Chin Med J (Engl); 2020 Feb; 133(4):474-482. PubMed ID: 31977556
[TBL] [Abstract][Full Text] [Related]
3. How to Combine the Two Landmark Treatment Methods-Allogeneic Hematopoietic Stem Cell Transplantation and Chimeric Antigen Receptor T Cell Therapy Together to Cure High-Risk B Cell Acute Lymphoblastic Leukemia?
Zhang M; Huang H
Front Immunol; 2020; 11():611710. PubMed ID: 33384696
[TBL] [Abstract][Full Text] [Related]
4. Successful Treatment of TCF3-HLF-positive Childhood B-ALL with Chimeric Antigen Receptor T-Cell Therapy.
Wang T; Wan X; Yang F; Shi W; Liu R; Ding L; Tang Y; Luo C; Yang X; Ma Y; Wang X; Liang H; Li B; Lu J; Chen J
Clin Lymphoma Myeloma Leuk; 2021 Jun; 21(6):386-392. PubMed ID: 33640284
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of CD19 CAR-T cell therapy for acute lymphoblastic leukemia patients relapsed after allogeneic hematopoietic stem cell transplantation.
Cao XY; Li JJ; Lu PH; Liu KY
Int J Hematol; 2022 Sep; 116(3):315-329. PubMed ID: 35737192
[TBL] [Abstract][Full Text] [Related]
6. Factors associated with treatment response to CD19 CAR-T therapy among a large cohort of B cell acute lymphoblastic leukemia.
Zhang X; Yang J; Li J; Li W; Song D; Lu XA; Wu F; Li J; Chen D; Li X; Xu Z; Liu S; Li Z; Ying K; Lu P
Cancer Immunol Immunother; 2022 Mar; 71(3):689-703. PubMed ID: 34365516
[TBL] [Abstract][Full Text] [Related]
7. CRISPR/Cas9-Engineered Universal CD19/CD22 Dual-Targeted CAR-T Cell Therapy for Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia.
Hu Y; Zhou Y; Zhang M; Ge W; Li Y; Yang L; Wei G; Han L; Wang H; Yu S; Chen Y; Wang Y; He X; Zhang X; Gao M; Yang J; Li X; Ren J; Huang H
Clin Cancer Res; 2021 May; 27(10):2764-2772. PubMed ID: 33627493
[TBL] [Abstract][Full Text] [Related]
8. [Allogeneic donor-derived CD19 CAR-T therapy of relapsed B-cell acute lmphoblastic leukemia after allogeneic hematopoietic stem cell transplantation].
Ma RZ; He Y; Yang DL; Wei JL; Pang AM; Jiang EL; Wang JX; Han MZ; Zhang RL; Feng SZ
Zhonghua Xue Ye Xue Za Zhi; 2021 May; 42(5):383-389. PubMed ID: 34218580
[No Abstract] [Full Text] [Related]
9. CAR T cells with dual targeting of CD19 and CD22 in pediatric and young adult patients with relapsed or refractory B cell acute lymphoblastic leukemia: a phase 1 trial.
Cordoba S; Onuoha S; Thomas S; Pignataro DS; Hough R; Ghorashian S; Vora A; Bonney D; Veys P; Rao K; Lucchini G; Chiesa R; Chu J; Clark L; Fung MM; Smith K; Peticone C; Al-Hajj M; Baldan V; Ferrari M; Srivastava S; Jha R; Arce Vargas F; Duffy K; Day W; Virgo P; Wheeler L; Hancock J; Farzaneh F; Domning S; Zhang Y; Khokhar NZ; Peddareddigari VGR; Wynn R; Pule M; Amrolia PJ
Nat Med; 2021 Oct; 27(10):1797-1805. PubMed ID: 34642489
[TBL] [Abstract][Full Text] [Related]
10. CAR-T Cell Therapy for Acute Lymphoblastic Leukemia: Transforming the Treatment of Relapsed and Refractory Disease.
Pehlivan KC; Duncan BB; Lee DW
Curr Hematol Malig Rep; 2018 Oct; 13(5):396-406. PubMed ID: 30120708
[TBL] [Abstract][Full Text] [Related]
11. Combination of CD19 and CD22 CAR-T cell therapy in relapsed B-cell acute lymphoblastic leukemia after allogeneic transplantation.
Liu S; Deng B; Yin Z; Lin Y; An L; Liu D; Pan J; Yu X; Chen B; Wu T; Chang AH; Tong C
Am J Hematol; 2021 Jun; 96(6):671-679. PubMed ID: 33725422
[TBL] [Abstract][Full Text] [Related]
12. [Safety and efficacy of humanized CD19-targeted CAR-T cells in patients with relapsed/refractory acute B cell lymphoblastic leukemia].
Song FM; Hu YX; Zhang MM; Wu WW; Xu HJ; Zhang HS; Huang H; Wei GQ
Zhonghua Xue Ye Xue Za Zhi; 2022 Aug; 43(8):651-656. PubMed ID: 36709149
[No Abstract] [Full Text] [Related]
13. [Not Available].
Rahal I; Cabannes-Hamy A; Boissel N
Bull Cancer; 2018 Dec; 105 Suppl 2():S158-S167. PubMed ID: 30686354
[TBL] [Abstract][Full Text] [Related]
14. Allogeneic Donor-Derived Anti-CD19 CAR T Cell Is a Promising Therapy for Relapsed/Refractory B-ALL After Allogeneic Hematopoietic Stem-Cell Transplantation.
Hua J; Zhang J; Wu X; Zhou L; Bao X; Han Y; Miao M; Li C; Fu Z; Wu D; Qian W; Qiu H
Clin Lymphoma Myeloma Leuk; 2020 Sep; 20(9):610-616. PubMed ID: 32507386
[TBL] [Abstract][Full Text] [Related]
15. A Review of Clinical Outcomes of CAR T-Cell Therapies for B-Acute Lymphoblastic Leukemia.
Martino M; Alati C; Canale FA; Musuraca G; Martinelli G; Cerchione C
Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33670075
[TBL] [Abstract][Full Text] [Related]
16. Are CAR T cells better than antibody or HCT therapy in B-ALL?
Pulsipher MA
Hematology Am Soc Hematol Educ Program; 2018 Nov; 2018(1):16-24. PubMed ID: 30504287
[TBL] [Abstract][Full Text] [Related]
17. Bispecific CAR-T cells targeting both CD19 and CD22 for therapy of adults with relapsed or refractory B cell acute lymphoblastic leukemia.
Dai H; Wu Z; Jia H; Tong C; Guo Y; Ti D; Han X; Liu Y; Zhang W; Wang C; Zhang Y; Chen M; Yang Q; Wang Y; Han W
J Hematol Oncol; 2020 Apr; 13(1):30. PubMed ID: 32245502
[TBL] [Abstract][Full Text] [Related]
18. CD38-directed CAR-T cell therapy: a novel immunotherapy strategy for relapsed acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation.
Cui Q; Qian C; Xu N; Kang L; Dai H; Cui W; Song B; Yin J; Li Z; Zhu X; Qu C; Liu T; Shen W; Zhu M; Yu L; Wu D; Tang X
J Hematol Oncol; 2021 May; 14(1):82. PubMed ID: 34034795
[TBL] [Abstract][Full Text] [Related]
19. CD4/CD8 T-Cell Selection Affects Chimeric Antigen Receptor (CAR) T-Cell Potency and Toxicity: Updated Results From a Phase I Anti-CD22 CAR T-Cell Trial.
Shah NN; Highfill SL; Shalabi H; Yates B; Jin J; Wolters PL; Ombrello A; Steinberg SM; Martin S; Delbrook C; Hoffman L; Little L; Ponduri A; Qin H; Qureshi H; Dulau-Florea A; Salem D; Wang HW; Yuan C; Stetler-Stevenson M; Panch S; Tran M; Mackall CL; Stroncek DF; Fry TJ
J Clin Oncol; 2020 Jun; 38(17):1938-1950. PubMed ID: 32286905
[TBL] [Abstract][Full Text] [Related]
20. Chimeric Antigen Receptor T Cell Therapy for Acute Lymphoblastic Leukemia.
Badar T; Shah NN
Curr Treat Options Oncol; 2020 Feb; 21(2):16. PubMed ID: 32025828
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]